Switzerland Archives

autoimmune disorder eosinophilic esophagitis allergy milk calypso biotech

News and Trends 20 Feb 2019

Inflammatory Disease Treatment Backed by €20M Series A

The Swiss company Calypso Biotech has raised a sizeable €20M to fund its immunotherapy for an allergy-related inflammatory disease. The Series A round will help to develop Calypso’s antibody treatment for eosinophilic esophagitis, a condition where patients have an inflamed esophagus and difficulty swallowing. This condition is often linked with allergies to food, such as […]

February 20, 2019 - 2 minutesmins - By Jonathan Smith

arvelle therapeutics SK Biopharmaceuticals Axovant epilepsy

More News! 18 Feb 2019

Enormous Series A to Help Bring Epilepsy Drug to Market

One of the biggest Series A rounds in European biotech, €159M ($180M), has been raised by the Swiss company Arvelle Therapeutics to help commercialize its epilepsy drug. Formed just this month, Arvelle plans to submit an application for EMA approval for the small molecule drug cenobamate, which it has licensed from the South Korean company […]

February 18, 2019 - 2 minutesmins - By Jonathan Smith

More News! 8 Feb 2019

Swiss Firm Launches Cancer Test That Gives Results in Minutes

Lunaphore Technologies has launched a device for automated testing of cancer tissue samples that gives results in under 30 minutes. Lunaphore has developed a piece of next-generation equipment to perform immunohistochemistry (IHC) tests, a common technique used to find specific cancer biomarkers in tissue samples from cancer patients after a biopsy. The equipment, called LabSat, will […]

February 8, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

Philogen cancer immunotherapy antibody pharma t cell

News and Trends 25 Jan 2019

Swiss-Italian Biotech Bags Antibody Deals with Three Big Pharma

The Swiss-Italian company Philogen has announced three different partnerships with Novartis, Celgene, and Janssen to develop new forms of immunotherapy and small molecule drugs. Philogen develops immunocytokines, which are antibodies that are fused with proteins that modify the immune system to fight diseases such as cancer. For example, this treatment can bind to tumors and activate […]

January 25, 2019 - 2 minutesmins - By Jonathan Smith

PharmaBiome microbiome ulcerative colitis

Interview 23 Jan 2019

Tackling the Complexity of the Gut Microbiome for Better Treatments

An imbalance in gut microbe species is linked with gastrointestinal disease. Philip talked with the CEO and co-founder of the Swiss startup PharmaBiome, Tomas de Wouters, about the complexity of rebalancing the gut microbiome in these conditions. The microbiome is a hugely complex ecosystem of microbes living all around the body. Different parts of the […]

January 23, 2019 - 5 minutesmins - By Jonathan Smith

News and Trends 17 Jan 2019

Scientists Create Prosthetic Ears Using 3D Bioprinting

Swiss researchers are developing cellulose-based materials for 3D bioprinting, which could lead to implants such as prosthetic ears. 3D-printed implants have big potential in the field of regenerative medicine. Although still at an early stage, this technology is enabling the development of customized prosthetics, such as skin and joint cartilage. One big focus in […]

January 17, 2019 - 3 minutesmins - By Jonathan Smith

picometrics technologies Huntingtons disease neuron

News and Trends 15 Jan 2019

Huntington’s Could Be Diagnosed in Five Minutes With This Lab-on-a-Chip

Using a lab-on-a-chip device, Swiss scientists have found a way to diagnose the neurodegenerative condition Huntington’s disease from DNA in the blood in just five minutes, rather than the five hours currently required. When carrying out the diagnosis of Huntington’s patients, the patient’s DNA is typically extracted from white blood cells. Regions of the […]

January 15, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 7 Jan 2019

Swiss Firm Raises €67M to Take Genomics AI to Hospitals

SOPHiA GENETICS has completed a $77M (€67M) funding round that will expand the use of its artificial intelligence technology for genomics into hospitals across the world. The funding will mainly go towards the recruitment of new employees. The goal is to increase the number of hospitals using SOPHiA’s AI technology, particularly in the US, where […]

January 7, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Dec 2018

Robotic Organoid Platform to Boost Personalized Medicine

The Swiss biotech Sun Bioscience has launched a robotic platform designed to standardize the production of 3D cell models of organs called organoids, making it easier to personalize treatments to a patient. Organoids are clusters of cells grown in the lab, and developed into miniature organs, such as the brain or intestine. Often no bigger […]

December 11, 2018 - 3 minutesmins - By Jonathan Smith

More News! 15 Nov 2018

Soldier Bug Could Help Combat Antibiotic Resistance

A garden insect makes a molecule that attacks the cell wall of bacteria, providing a new potential weapon in the fight against antibiotic resistance. Thanatin is a peptide molecule produced by the spined soldier bug Podisus maculiventris to control the types of bacteria that live in its gut. A research group from the University of Zurich […]

November 15, 2018 - 2 minutesmins - By Jonathan Smith

Interview 31 Oct 2018

Biotech Investment Strategies: How, When and Where to Invest

How, when and where to invest in a biotech company can be essential to the success of both specialized investors and the companies receiving the money. At Refresh Basel, I spoke to Chandra Leo, Partner at the life sciences VC firm HBM Partners, to discuss investment strategies in biotech and his advice for companies seeking […]

October 31, 2018 - 6 minutesmins - By Clara Rodríguez Fernández

axovant parkinsons disease neuron dopamine

News and Trends 25 Oct 2018

Parkinson’s Disease Gene Therapy Clinical Trial Launched in UK

A gene therapy for Parkinson’s disease developed by Swiss biotech Axovant has been used on the first patient in a Phase I/II trial at University College London. Parkinson’s disease is a neurodegenerative disease, caused by a lack of the neurochemical dopamine in regions of the brain handling motor functions causing debilitating symptoms such as rigidity […]

October 25, 2018 - 2 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us